Lawsuit a Catalyst for LDT Regulation Progress?

We have written extensively about health system regulation in this blog, with a keen interest in how LDT regulation will shake out.  In our other blog we’ve even argued strongly for caution in LDT regulation, primarily to avoid stifling innovation.  However, our...

Unique Biomarkers Are Associated With More Drug Approvals

In our Chart of the Week post from last week we presented an analysis of the number of unique biomarkers being used by leading drug developers in their clinical trials (unique biomarkers being defined as those that aren’t being used by any other companies). This...

Chart of the Week: Algorithms Slow Test Review Period

Diagnostic tests with algorithms seem to slow review periods on average. Share this Image On Your Site <p><strong>Please include attribution to https://amplion.wpengine.com/biomarker-trends with this graphic.</strong><br /><br /><a...

[Infographic]: A Visual History of LDT Regulation

We’ve covered the LDT regulation evolution for some time now.  To give some perspective we’ve created the following infographic showing the history of LDT regulation.  To use it in your own content check out the code snippet below the infographic.  We only...